bullish
Boryung Pharmaceutical (003850 KS): Strong 4Q22 Result; New Drugs to Drive Long-Term Growth
351 Views12 Apr 2023 21:07
Boryung reported 21% revenue growth in Q4, driven by prescription drugs. New in-licensed oncology as well as other drug launches this year should drive double-digit revenue growth.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Boryung Pharmaceutical (003850 KS): Prescription Drugs Took a Breather in Q3; Poised to Rebound17 Dec 2023
- Boryung Pharmaceutical (003850 KS): 2Q23 Marks Six Consecutive Quarters of Revenue Growth31 Aug 2023
- Boryung Pharmaceutical (003850 KS): Strong 4Q22 Result; New Drugs to Drive Long-Term Growth12 Apr 2023
- Boryung Pharmaceutical (003850 KS): Oncology Portfolio Expansion to Accelerate Growth Momentum30 Sep 2022
- Boryung Pharmaceutical (003850 KS): Focus on Prescription Drugs for Stability and Accelerated Growth11 Jun 2022
x